Laura Clifton‐Hadley

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Claire Roddie, Juliana Dias, Maeve O’Reilly et al. · Journal of Clinical Oncology · 2021 · 133 citations · Full text

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial

Peter Hoskin, B. Popova, Oliver Schofield et al. · The Lancet Oncology · 2021 · 104 citations

Lymphoid Neoplasia, Gy Radiotherapy, Surgical Oncology +9

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia

Claudia Rössig, Martin Pulé, Bianca Altvater et al. · Leukemia · 2017 · 80 citations

Vaccination, Cell Therapy, Immunology +5

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Richard A. Anderson, Rachel Remedios, Amy A. Kirkwood et al. · The Lancet Oncology · 2018 · 77 citations · Full text

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Anthony V. Moorman, Emilio Barretta, Ellie Butler et al. · Leukemia · 2021 · 59 citations · Full text